Aratana Therapeutics Stock Fundamentals
Aratana Therapeutics fundamentals help investors to digest information that contributes to Aratana Therapeutics' financial success or failures. It also enables traders to predict the movement of Aratana Stock. The fundamental analysis module provides a way to measure Aratana Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aratana Therapeutics stock.
Aratana |
Aratana Therapeutics Company Return On Equity Analysis
Aratana Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Aratana Therapeutics Return On Equity | -0.0016 |
Most of Aratana Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aratana Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Aratana Therapeutics has a Return On Equity of -0.0016. This is 99.99% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 99.48% lower than that of the firm.
Aratana Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Aratana Therapeutics's current stock value. Our valuation model uses many indicators to compare Aratana Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aratana Therapeutics competition to find correlations between indicators driving Aratana Therapeutics's intrinsic value. More Info.Aratana Therapeutics is considered to be number one stock in return on equity category among related companies. It is considered to be number one stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Aratana Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Aratana Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Aratana Therapeutics' earnings, one of the primary drivers of an investment's value.Aratana Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aratana Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aratana Therapeutics could also be used in its relative valuation, which is a method of valuing Aratana Therapeutics by comparing valuation metrics of similar companies.Aratana Therapeutics is currently under evaluation in return on equity category among related companies.
Aratana Fundamentals
| Return On Equity | -0.0016 | |||
| Return On Asset | -0.0012 | |||
| Profit Margin | (0) % | |||
| Operating Margin | (28.45) % | |||
| Current Valuation | 211.52 M | |||
| Shares Outstanding | 48.62 M | |||
| Shares Owned By Insiders | 3.31 % | |||
| Shares Owned By Institutions | 71.89 % | |||
| Number Of Shares Shorted | 763.7 K | |||
| Price To Earning | (3.72) X | |||
| Price To Book | 2.48 X | |||
| Price To Sales | 6.24 X | |||
| Revenue | 38.73 M | |||
| Gross Profit | 24.76 M | |||
| EBITDA | (10.02 M) | |||
| Net Income | (12.96 M) | |||
| Cash And Equivalents | 37.06 M | |||
| Cash Per Share | 0.76 X | |||
| Total Debt | 796 K | |||
| Debt To Equity | 0.80 % | |||
| Current Ratio | 6.66 X | |||
| Book Value Per Share | 2.60 X | |||
| Cash Flow From Operations | (3.54 M) | |||
| Short Ratio | 1.49 X | |||
| Earnings Per Share | (0.27) X | |||
| Price To Earnings To Growth | (0.89) X | |||
| Number Of Employees | 83 | |||
| Beta | 0.06 | |||
| Market Capitalization | 241.09 M | |||
| Total Asset | 147.07 M | |||
| Retained Earnings | (222.83 M) | |||
| Working Capital | 83.33 M | |||
| Current Asset | 89.02 M | |||
| Current Liabilities | 5.68 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Other Consideration for investing in Aratana Stock
If you are still planning to invest in Aratana Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aratana Therapeutics' history and understand the potential risks before investing.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |